Fas ligand (FasL), an apoptosis-inducing member of the TNF cytokine family and its receptor, Fas, are critical for shutdown of chronic immune responses1-3 and prevention of autoimmunity4,5. Accordingly, mutations in their genes cause severe lymphadenopathy and autoimmune disease in mice6,7 and humans8,9. FasL function is regulated by deposition in the plasma membrane and metalloprotease-mediated shedding10,11. We generated gene-targeted mice that selectively lack either secreted FasL (ΔsFasL) or membrane-bound FasL (ΔmFasL) to resolve which of these forms is required for cell killing and to explore their hypothetical nonapoptotic activities. Mice lacking sFasL (FasL Δs/Δs ) appeared normal and their T cells readily killed target cells, whereas T cells lacking mFasL (FasL Δm/Δm ) could not kill cells through Fas activation. FasL Δm/Δm mice developed lymphadenopathy and hyper-gammaglobulinaemia, similar to FasL gld/gld mice, which express a mutant form of FasL that cannot bind Fas, but surprisingly, (on a C57BL/6 background) FasL Δm/Δm mice succumbed to SLE-like autoimmune kidney destruction and histiocytic sarcoma, diseases that occur only rarely and considerably later in FasL gld/gld mice. These results demonstrate that mFasL is essential for cytotoxic activity and constitutes the guardian against lymphadenopathy, autoimmunity and cancer whereas excess sFasL appears to promote autoimmunity and tumorigenesis through non-apoptotic activities.
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apoptosis; Fas ligand; autoimmunity; cancer; allergy Although Fas-induced apoptosis is thought to require extensive aggregation of preassembled Fas trimers12-15, it has not been resolved whether mFasL, sFasL or both cause cell killing when expressed physiologically 4,5. It is also debated whether either or both of these forms of FasL may have non-apoptotic activities, such as induction of inflammatory responses5, 16, 17 . Indeed, sFasL is capable of activating the NF-κB pathway (Supplementary Fig. 1 and 18,19) . We sought to determine the physiological functions of mFasL and sFasL by generating gene-targeted mice that cannot shed FasL but do express membrane-bound FasL (FasL Δs/Δs ) or conversely mice that lack membrane-bound FasL but are capable of producing sFasL (FasL Δm/Δm ). Studies using FasL over-expression in transfected cell lines showed that the former can be accomplished, by mutating the sequences in the fasl gene encoding the amino acids required for metalloprotease-mediated cleavage12-14 ( Fig. 1a, Supplementary Fig. 2a,b,d ). Conversely, the latter can be achieved by replacing the sequences in the fasl gene encoding the trans-membrane and intra-cellular regions of FasL with those encoding the signal peptide of the cytokine G-CSF12-14 ( Fig. 1a , Supplementary Fig. 2a ,c,e).
To verify that the mutations had the intended consequences, we compared the expression and subcellular localisation of FasL between mitogenically activated T lymphocytes from FasL Δs/Δs , FasL Δm/Δm and wt mice. Immunofluorescent staining and confocal microscopic analysis of fixed cells showed that intracellular localisation and levels of the FasL Δs and FasL Δm mutant proteins were comparable to those of wt FasL (Fig. 1b) . ELISA demonstrated that mitogen-activated T cells from FasL Δm/Δm and wt mice contained substantial levels of FasL in their supernatants whereas FasL Δs/Δs T cells had significantly less (Fig. 1c) . FasL in cellular supernatants can be found in two forms: secreted sFasL derived by metalloprotease-mediated cleavage or mFasL present on vesicles that had been shed by cells12. The latter can efficiently trigger Fas-mediated apoptosis in cultured cells12, although the physiological relevance of this remains unclear. Regardless, FPLC and ultracentrifugation revealed that in contrast to FasL from supernatants of wt or FasL Δm/Δm T cells, a substantial fraction of FasL in supernatants of FasL Δs/Δs T cells resided in membranous fractions ( Supplementary Fig. 3 ). Finally, immunofluorescent cell surface staining and FACS analysis identified significantly higher levels of membrane-bound FasL on activated T cells from FasL Δs/Δs mice compared to wt T cells (Fig. 1d) , consistent with the notion that metalloprotease-mediated cleavage reduces the levels of mFasL11-14. As expected, no FasL was detected on the surface of FasL Δm/Δm T cells (Fig. 1e) . These results verify that FasL Δs/Δs mice produce mFasL that cannot be shed by metalloproteases, whereas FasL Δm/Δm mice lack mFasL but produce sFasL.
Since FasL contributes to the killing of virus-infected and other target cells4, we examined which form is critical. We used mitogen-activated T cells from wt or the mutant fasl knockin mice as killers and the FasL sensitive CH1 mouse B lymphoma cells ( Supplementary Fig.  4a,b) as targets. FasL Δs/Δs T cells killed CH1 cells with significantly higher efficiency than wt T cells (Fig. 2a) . In contrast, FasL Δm/Δm T cells possessed only poor cytotoxic activity, comparable to those from FasL-deficient FasL gld/gld mice (Fig. 2b) Fig. 4c-e) , demonstrating that only the former triggered a FasL/Fas-dependent apoptotic process. Restimulation of activated T cells in vitro causes activation induced cell death (AICD), which is largely dependent on FasL-mediated (paracrine and/or autocrine) Fas activation4. Stimulation with mitogenic antibodies to CD3 triggered AICD in FasL Δs/Δs T cell blasts as efficiently as in wt T cell blasts (Fig. 2c) . In contrast, AICD was abnormally reduced in FasL Δm/Δm T cells, indeed to a similar extent as seen with their FasL gld/gld counterparts (Fig. 2d) Fig. 5 ). This is consistent with the notion that AICD involves FasL/Fas-dependent as well as -independent mechanisms4,20. Collectively, these results demonstrate that mFasL but not sFasL is essential for Fas-induced killing of target cells and AICD and they indicate that metalloprotease-mediated cleavage of mFasL reduces the cytotoxic activity of activated T cells. This is consistent with certain findings with transfected cell lines over-expressing FasL12-14 and the notion that apoptosis induction requires not only binding of FasL trimers to pre-assembled Fas trimers but more extensive aggregation of Fas trimers12-15. This contrasts with TNFα, which can kill TNF-R1 + target cells in both membrane-bound as well as secreted form4,5.
Defects in AICD of mature T cells are thought to be the cause of the lymphadenopathy, hyper-gammaglobulinaemia and autoimmunity in mice and humans deficient in FasL (e.g. FasL gld/gld ) or Fas (e.g. Fas lpr/lpr )4. As reported21, by ∼100 days of age FasL gld/gld mice (on an inbred C57BL/6 background) started to show signs of lymphadenopathy and splenomegaly (Fig. 3a,b ), including accumulation of large numbers of 'unusual' TCRα/ β + CD4 -CD8 -B220 + T cells (Fig. 3c,d ). This was accompanied by hypergammaglobulinaemia ( Fig. 3e ) with high titers of anti-nuclear auto-antibodies (ANA, Fig.  3f,g ). FasL Δm/Δm mice developed lymphadenopathy, splenomegaly, hypergammaglobulinaemia and ANA at a similar rate and extent as FasL gld/gld mice (Fig. 3) . Remarkably, however, the titres of anti-DNA auto-antibodies were significantly higher in FasL Δm/Δm mice compared to FasL gld/gld mice (67% vs 14% symptomatic of SLE-like disease (>12 IU/mL), p<0.05; Fig. 3h ). In contrast, FasL Δs/Δs mice exhibited none of these abnormalities and had a normal lifespan ( Supplementary Fig. 6 ). These results show that mFasL but not sFasL is essential for the killing of unwanted lymphocytes that is required to prevent lymphadenopathy, hyper-gammaglobulinaemia and accumulation of autoantibodies.
FasL gld/gld mice express a mutated FasL gld protein (in membrane-bound and secreted form) that is unable to bind to its receptor Fas7, whereas the secreted FasL Δm protein (like wt sFasL) can bind to Fas ( Supplementary Fig. 1 and12-14) . If sFasL plays a role in inflammation, for example through NF-κB activation (Supplementary Fig. 1 and 18,19) , one would expect significant differences in morbidity and mortality between FasL Δm/Δm and FasL gld/gld mice. It was therefore remarkable that FasL Δm/Δm mice became sick significantly earlier than FasL gld/gld mice (Fig. 4a, median latency 406 vs 658 days; p<0.0001) . At autopsy 62% of terminally ill FasL Δm/Δm mice showed signs of SLE-like autoimmune disease, including cellular crescents, protein casts (Fig. 4b,c) , deposition of IgM as well as IgG antibodies and complement in renal glomeruli ( Supplementary Fig. 7 ). In contrast, such pathologies were only rarely observed in FasL gld/gld mice, and then only at a considerably older age and with less severity. Remarkably, by 400 days ∼50% of FasL Δm/Δm but only ∼15% of the FasL gld/gld mice had developed fatal SLE-like autoimmune kidney disease (Fig. 4b) .
By 5 months 46% of FasL Δm/Δm mice presented with very high (>3000 ng/mL) serum IgE levels and ∼30% had developed severe dermatitis with lesions appearing on their ears and necks ( Supplementary Fig. 8a,b) . Although not previously reported, we observed this autoimmune pathology also in some FasL gld/gld mice, albeit at decidedly lower incidence (∼10%) and later in life compared to FasL Δm/Δm mice. In Fas lpr/lpr mice lymphadenopathy and accumulation of TCRα/β + CD4 -CD8 -B220 + T cells are accompanied by abnormally increased serum levels of pro-inflammatory cytokines, including TNFα, IL-6, Ifnγ and FasL itself22. FasL was shown to activate NF-κB transcription factors and expression of proinflammatory cytokines and chemokines ( Supplementary Fig. 1 5,18,19 ). We therefore hypothesised that FasL Δm/Δm mice may develop autoimmune disease more rapidly and at higher incidence than FasL gld/gld animals because only the former produce excess sFasL that can bind to its receptor Fas, which may then activate NF-κB and thereby drive production of pro-inflammatory cytokines ( Supplementary Figs. 8 and 9 ). Consistent with this idea, at 3-5 months FasL Δm/Δm mice contained substantial numbers of cells with high levels of nuclear (i.e. active) p65/NF-kB in the spleen, liver (Supplementary Fig. 10 ) and kidneys (not shown) and high serum levels of TNFα (Supplementary Fig. 8 ; p<0.0001 for TNFα). These abnormalities were significantly less prevalent in FasL gld/gld mice and were not detected in FasL Δs/Δs or wt animals ( Supplementary Figs. 8, 9 and 10).
Fas is expressed on hepatocytes and its activation causes apoptosis23,24. FasL can also be found in the liver, produced by infiltrating T lymphocytes or resident myeloid cells, and it has therefore been hypothesised that FasL-Fas induced apoptosis prevents tumorigenesis in this organ25. Interestingly, a significant fraction (27% by 18 months) of both strains of FasL Δm/Δm mice developed hepatic tumours with deposits in the spleen and lungs (Fig.  4d,e) . Microscopically and by immuno-phenotype (Mac-1 + Mac-2 + F4/80 + B220 -Thy-1 -CD3 -) these tumours were characteristic of histiocytic sarcoma (Fig. 4e,f and Supplementary Fig.  11 ), being composed of oval cells with eosinophilic cytoplasm and elongated or folded nuclei26. These tumours were transplantable in C57BL/6 mice ( Supplementary Fig. 11 ), confirming their malignant status. Histiocytic sarcoma was rarely seen in FasL Δs/Δs or FasL gld/gld animals and in C57BL/6 (wt) mice such tumours are observed only at very low frequency late in life (∼5% >18 months26,27; Fig. 4d and Supplementary Fig. 6 ).
Our findings that mFasL but not sFasL is critical for AICD of T cells in vitro and for prevention of lymphadenopathy, hyper-gammaglobulinemia and accumulation of autoantibodies within the whole animal are consistent with the notion that repeated TCR stimulation kills chronically activated T cells that are specific for auto-antigens or persistent pathogens through FasL-Fas signalling, thereby preventing lymphadenopathy1-4. The observation that FasL Δm/Δm mice develop SLE-like glomerulonephritis and histiocytic sarcoma considerably earlier and with higher incidence than FasL gld/gld mice indicates that the high levels of sFasL produced in the FasL Δm/Δm mice, which in contrast to FasL gld can engage its receptor Fas12,13, may promote autoimmunity and tumorigenesis. sFasL may achieve this by triggering non-apoptotic signalling pathways, such as NF-κB-dependent inflammatory processes. Alternatively, differences between FasL gld/gld and FasL Δm/Δm mice may be due to the fact that retrograde signalling through FasL28,29 can only occur in the former but not the latter, although upon challenge with influenza virus in vivo or stimulation with suboptimal doses of anti-CD3 antibodies in vitro, CD8 + T cell responses were indistinguishable between wt, FasL gld/gld and FasL Δm/Δm mice ( Supplementary Figures 12  and 13 ). It is theoretically also possible that FasL Δm/Δm mice die earlier than FasL gld/gld mice because the FasL Δm mutation causes complete loss of function whereas FasL gld represents a partial loss of function mutation. For two reasons this appears unlikely: (1) lymphadenopathy and hyper-gammaglobulinemia occur in the two mutant strains (FasL Δm/Δm and FasL gld/gld ) with comparable kinetics and magnitude (Fig. 3) , indicating that the two mutations do not differ markedly in their potency, and (2) histiocytic sarcoma has not been reported in FasL knock-out mice30. We therefore hypothesise that tumorigenesis may be driven by a combination of loss of mFasL-mediated apoptosis of cells undergoing transformation and sFasL-Fas induced non-apoptotic signals, perhaps NF-κB-mediated stimulation of cell proliferation, survival and/or inflammation within an elevated cytokine milieu.
Methods Summary Generation of FasL mutant mice
The mouse fasl locus and known restriction sites were used to construct the targeting vector and diagnose homologous recombination in embryonic stem (ES) cells and gene-targeted (FasL Δm/Δm , FasL Δs/Δs ) mice. Targeting knock-in vectors were made with the loxP/ pGKNeo/loxP cassette cloned into the Pac1 site. Targeting constructs for the mutant FasL mice ( Supplementary Fig. 2 ) were linearised and electroporated into C57BL/6-derived Bruce-4 ES cells.
Analysis of FasL mutant mice
All experiments with mice were performed according to the guidelines of the Animal Ethics committees of our institutions. Mice were killed at 6, 12 or 20 weeks for analysis and further cohorts were monitored daily for morbidity and killed when showing signs of illness. Tissues were fixed for microscopic analysis in 80% Histochoice (Amresco)/20% ethanol or 10% buffered formalin and embedded in paraffin and conventional histopathology was performed on hematoxylin plus eosin stained sections. For detailed methods for immunohistochemical staining, immunofluorescent staining, confocal microscopy, cell preparation, flow cytometric analysis, ELISA, AICD, chromatography, viral infection and target cell killing, T cell proliferation assays and Western blotting refer to the online methods version.
Statistical analysis was performed using the student's T-test, log rank (Mantel-Cox) test for survival curves or one-way analysis of variance using Turkey's comparison test to compare multiple groups where appropriate.
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